Sutro Biopharma, Inc. STRO NASDAQ

Sutro Biopharma, Inc. (STRO) reported total assets of $173.83M and total liabilities of $306.28M for quarter ending 2025-12-31, resulting in total equity of $-132.45M.

The company held $141.43M in cash and short-term investments. Total debt stood at $235.21M, with net debt of $177.08M. The Debt-to-Equity (D/E) ratio was -1.78 (conservative).

Current ratio is 2.01, indicating strong short-term liquidity. Interest coverage is -3.5x (weak).

Criteria supported by this page:

• HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (58/100) — Total assets $173.83M and equity $-132.45M support the company's competitive scale
• VALUE (63/100) — Debt-to-Equity -1.78 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 42/100 with 1/7 criteria passed.